Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00WBN
|
||||
| Former ID |
DIB008021
|
||||
| Drug Name |
ALV-003
|
||||
| Synonyms |
Gluten-detoxifying protease (celiac sprue), Alvine Pharmaceuticals; Glutamine-specific cysteine protease (EP-B2) + proline-specific prolyl endopeptidase (PEP) (celiac disease), Alvine
|
||||
| Indication | Celiac disease [ICD9: 579; ICD10:K90.0] | Phase 2 | [1] | ||
| Company |
Alvine Pharmaceuticals Inc
|
||||
| Target and Pathway | |||||
| Target(s) | Prolyl endopeptidase | Target Info | Modulator | [2] | |
| KEGG Pathway | Renin-angiotensin system | ||||
| PANTHER Pathway | Vasopressin synthesis | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00959114) Safety and Efficacy of ALV003 for the Treatment of Celiac Disease. U.S. National Institutes of Health. | ||||
| REF 2 | The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clin Immunol. 2010 Mar;134(3):289-95. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.